UroGen Pharma shares are trading lower. The company announced a strategic Option and Research License Agreement and a related equity investment agreement with IntraGel Therapeutics.

Benzinga Newsdesk www.benzinga.com Negative 39.5%

Neg 39.5% Neu 0% Pos 0%

Comments

No comments yet. Be the first!